NO ESCALATION, HEMOSTASIS, INFLAMMATION AND SICKLE CELL DISEASE

无升级、止血、炎症和镰状细胞病

• 批准号: 7605112
• 负责人: RACHELLE F NUSS
• 金额: $ 0.7万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605112
• 关键词: Accounting; Computer Retrieval of Information on Scientific Projects Database; Deposition; Equilibrium; Fibrin; Funding; Grant; Hemostatic Agents; Hemostatic function; Inflammation; Inflammatory; Institution; Mediator of activation protein; Morbidity - disease rate; Nitric Oxide; Research; Research Personnel; Resources; Sickle Cell Anemia; Source; Tissues; United States National Institutes of Health; improved; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nitric oxide availability is reduced in people with sickle cell disease. Possibly, as a consequence, hemostasis is deregulated and circulating inflammatory mediators are present. Excess fibrin deposition in tissues ensues and accounts for much of the morbidity and mortality. We postulate administration of NO may improve hemostatic and inflammatory balance thereby potentially reducing the consequences of sickle cell disease.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 镰状细胞病患者体内一氧化氮的可用性降低。因此，止血可能失调，并存在循环炎症介质。组织中过量的纤维蛋白沉积增加并导致大部分的发病率和死亡率。我们推测NO的施用可以改善止血和炎症平衡，从而潜在地减少镰状细胞病的后果。